SVF
Level A· Stronger Clinical EvidenceSystematic Review

A systematic review of clinical efficacy and safety of cell-based therapies in Alzheimer's disease.

Feizi H., Hosseini MS., Seyedi-Sahebari S., Karimi H., Mosaddeghi-Heris R., Sadigh-Eteghad S.

Systematic Review with a reported sample of 59 on Neuroinflammation, published in Dement Neuropsychol (2024) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Dement Neuropsychol (2024)
Country
Brazil
Reported sample size
59
PMID
39258164
DOI
10.1590/1980-5764-DN-2024-0147
NCT
NCT03117738

Abstract (original English)

There is presently no disease-modifying therapy for Alzheimer's Disease (AD), which is the most prevalent cause of dementia. This study aspires to estimate the efficacy and safety of cell-based treatments in AD. Observing the Joanna Briggs Institute (JBI) methods and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, a systematic search was accomplished in PubMed, Medical Literature Analysis and Retrieval System Online (Medline, via Ovid), Embase; Cochrane, and Cumulative Index of Nursing and Allied Health Literature - CINAHL (via EBSCO) databases up to June 2023. The relevant clinical studies in which cell-based therapies were utilized to manage AD were included. The risk of bias was evaluated using the JBI checklists, based on the study designs. Out of 1,014 screened records, a total of five studies with 70 individuals (including 59 patients receiving stem cells and 11 placebo controls) were included. In all these studies, despite the discrepancy in the origin of stem cells, cell density, and transplant site, safety goals were obtained. The intracerebroventricular injection of adipose-derived stromal vascular fraction (ADSVF) and umbilical cord-derived mesenchymal stem cells (UC-MSCs), the intravenous injection of Lomecel-B, and the bilateral hippocampi and right precuneus injection of UC-MSCs are not linked to any significant safety concer

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HipSystemic / IVNeuroinflammation
View on PubMedDOI

Related research